Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 79 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Islet Cell Transplantation Clear all
Not listed Phase 1 Interventional

Modification of the "Edmonton Protocol" to Allow for Successful Islet Transplantation From a Single Pancreas and Extension of the "Edmonton Protocol" to Kidney Transplant Recipients

NCT00021580
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
human cadaveric islet cell transplantation
Procedure
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 21, 2026, 4:04 PM EDT
Approved For Marketing No phase listed Expanded access

Islet Transplantation in Type I Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol

NCT03791567
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Donislecel (allogeneic islets of Langerhans for transplant)
Biological
Lead sponsor
CellTrans Inc.
Industry
Eligibility
18 Years to 75 Years
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Jul 21, 2026, 4:04 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Allogenic Islet Cell Transplantation

NCT00160732
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Allogenic islet cells (human, U. Chicago), Intraportal infusion of islet cells
Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 58 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Jul 21, 2026, 4:04 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation

NCT01206101
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Duarte, California • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Jul 21, 2026, 4:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pancreatic Islet Transplantation Into the Gastric Submucosa

NCT01571817
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Isolated Human Pancreatic Islets
Biological
Lead sponsor
Andrew Posselt
Other
Eligibility
18 Years to 90 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Jul 21, 2026, 4:04 PM EDT
Recruiting Phase 1Phase 2 Interventional

Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye

NCT02846571
View directory record Official record
Conditions
Diabetes
Interventions
Human Pancreatic Islet Transplantation
Biological
Lead sponsor
Midhat H. Abdulreda
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Jul 21, 2026, 4:04 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet Transplantation

NCT01817959
View directory record Official record
Conditions
Islet Transplantation in Diabetes Mellitus Type 1
Interventions
Reparixin, Placebo
Drug
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years to 70 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Jul 21, 2026, 4:04 PM EDT
Terminated Phase 2 Interventional Results available

Islet Cell Transplantation Alone and CD34+ Donor Bone Marrow Cell Infusion in Type 1 Diabetes Mellitus

NCT00315614
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Islet Transplantation and Bone Marrow
Biological
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Jul 21, 2026, 4:04 PM EDT
Completed No phase listed Observational

Screening for Patients Needing Kidney, Kidney-Pancreas, or Islet-Cell Transplant

NCT00001859
View directory record Official record
Conditions
Diabetes Mellitus, Kidney Failure
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jul 21, 2026, 4:04 PM EDT
Recruiting Phase 1Phase 2 Interventional

Improving Islet Transplantation Outcomes With Gastrin for Type I Diabetes

NCT03746769
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Allogenic Human Islet Cells, Gastrin 17
Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 68 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jul 21, 2026, 4:04 PM EDT
Active, not recruiting Phase 2 Interventional

Islet Cell Transplant for Type 1 Diabetes

NCT01909245
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Allogenic Human Islet Cells, Immunosuppressive Agents, Gastrin 17
Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 68 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jul 21, 2026, 4:04 PM EDT
Not listed Phase 1 Interventional

Treatment of Type I Diabetes by Islet Transplantation Into the Gastric Submucosa Study Protocol

NCT02402439
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Islet cells, Islet transplantation into the gastrointestinal submucosa
Drug · Procedure
Lead sponsor
Andrew Posselt
Other
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Jul 21, 2026, 4:04 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch™ for Clinical Islet Transplantation

NCT03513939
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Sernova Cell Pouch
Combination Product
Lead sponsor
Sernova Biotherapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jul 21, 2026, 4:04 PM EDT
Completed No phase listed Observational

Screening of Subjects With Type I Diabetes to Determine Eligibility for Islet Transplantation

NCT02004964
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Rodolfo Alejandro
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Jul 21, 2026, 4:04 PM EDT
Terminated Phase 1Phase 2 Interventional

Cadaveric Islet Transplantation in Patients With Insulin-Dependent Diabetes Mellitus

NCT00579371
View directory record Official record
Conditions
Islets of Langerhans Transplantation, Diabetes Mellitus, Type 1
Interventions
Islets of Langerhans
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Jul 21, 2026, 4:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

MGA031, Sirolimus and Tacrolimus in Islet Transplantation

NCT00265473
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Hypoglycemia
Interventions
Allogeneic Islets of Langerhans
Biological
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Jul 21, 2026, 4:04 PM EDT
No Longer Available No phase listed Expanded access

Immunosuppressive Medications for Participants in ITN005CT (NCT00014911)

NCT01309022
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Sirolimus, Tacrolimus, Mycophenolate mofetil, Mycophenolic acid
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
U.S. locations
3
States / cities
Miami, Florida • Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Jul 21, 2026, 4:04 PM EDT
Completed Phase 2 Interventional

Islet Cell Transplantation Alone in Patients With Type 1 Diabetes Mellitus: Steroid-Free Immunosuppression

NCT00306098
View directory record Official record
Conditions
Diabetes Mellitus, Type I
Interventions
islets
Drug
Lead sponsor
Rodolfo Alejandro
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 3, 2024 · Synced Jul 21, 2026, 4:04 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus

NCT06575426
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Hypoglycemia, Islet Cell Transplantation, Type 1 Diabetes, Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus, Type 1 Diabetes (T1D), Severe Hypoglycemia, Xenotransplantation, Hypoglycemic Episode, Islet Transplantation in Diabetes Mellitus Type 1, Glucose Metabolism Disorders (Including Diabetes Mellitus), Immune System Diseases, Autoimmune Diseases, Metabolic Disease
Interventions
OPF-310
Combination Product
Lead sponsor
Otsuka Pharmaceutical Factory, Inc.
Industry
Eligibility
35 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Jul 21, 2026, 4:04 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Single Center Study of Islet Transplantation in Non-uremic Diabetic Patients

NCT01897688
View directory record Official record
Conditions
Type 1 Diabetes, Severe Hypoglycemic Unawareness
Interventions
Islet Cell Transplant
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 21, 2026, 4:04 PM EDT
Completed Phase 2 Interventional

LEA29Y (Belatacept) Emory Edmonton Protocol

NCT00468403
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Allogeneic Pancreatic Islet Cells, Belatacept, Basiliximab, Mycophenolate Mofetil, Tacrolimus, Intraportal infusion of islet cells
Biological · Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 6, 2016 · Synced Jul 21, 2026, 4:04 PM EDT
Active, not recruiting Phase 1 Interventional

Islet Transplantation Alone (ITA) in Patients With Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive Regimen

NCT00706420
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Islet Transplantation + Immunosuppression, Islet cell transplantation
Procedure · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Jul 21, 2026, 4:04 PM EDT
Terminated Phase 1 Interventional

Islet Cell Transplants for Diabetes

NCT00303134
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Islet Cell Transplantation
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2019 · Synced Jul 21, 2026, 4:04 PM EDT
Completed Phase 1Phase 2 Interventional

Pancreatic Islets and Parathyroid Gland Co-transplantation for Treatment of Type 1 Diabetes

NCT03977662
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Co-transplantation of PTG with pancreatic islets
Combination Product
Lead sponsor
Peter Stock
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jul 21, 2026, 4:04 PM EDT